RICT 2023

57th International Conference on Medicinal Chemistry

Drug Discovery and Selection

 Lille, France    July 5-7, 2023

Programme


07:30

Registration

08:45

Opening Ceremony

Mrs Mady DORCHIES-BRILLON
RÉGION HAUTS-DE-FRANCE, LILLE, France
Prof. Franck DUMEIGNIL
UNIVERSITY OF LILLE, Lille, France
Dr Jean-Yves ORTHOLAND
EDELRIS, Lyon, France
Prof. Nicolas WILLAND
INSERM - UNIVERSITÉ DE LILLE / INSTITUT PASTEUR OF LILLE, Lille, France

Session 1: Hit Finding

Session chair

Dr Priscille BRODIN
INSERM - UNIVERSITÉ DE LILLE, Lille, France
09:15

PL01 - Fragment-based Design of Methionine Adenosyl Transferase (MAT2a) Inhibitors with Anti-tumour Effect

Dr Marianne SCHIMPL
ASTRAZENECA, Cambridge, United Kingdom
09:50

PL02 - Identification of CDK8 Inhibitors as Inducers of Tendon Cell Differentiation through Phenotypic Screening and Chemoproteomics

Dr Jean-Baptiste LANGLOIS
NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland
10:25

Coffee Break sponsored by Merck, Networking & Exhibition

Session 2: New Avenues in Drug Discovery Chemistry

Session chair

Dr Jean QUANCARD
NOVARTIS, Basel, Switzerland
10:55

PL03 - Discovery of Novel Microbiome-Sparing Antibiotics with Activity Against Gram-Negative Pathogens

Prof. Paul J. HERGENROTHER
UNIVERSITY OF ILLINOIS, Urbana, United States
11:30

PL04 - Electrochemistry in High-Throughput

Dr Nessa CARSON
ASTRAZENECA, Macclesfield, United Kingdom
12:05

OC01 - Experiences from CETSA Screens for Hit Discovery versus Challenging Targets

Dr Alice LANNE
ASTRAZENECA, Macclesfield, United Kingdom
12:25

Lunch, Networking & Exhibition

13:15

Poster Session I (posters with odd numbers), Networking & Exhibition

Session 3: New Molecular Landscapes in Drug Discovery

Session chair

Dr Nicolas GEORGE
AQEMIA, Paris, France
14:45

PL05 - Stabilizing Relevant GPCR Conformations to Discover Therapeutic Antibodies

Dr Christel MENET
CONFO THERAPEUTICS, Brussels, Belgium
15:20

PL06 - LipMete (Lipophilic Metabolism Efficiency) as a Simple Guide for Half-Life and Dosing Regimen Prediction of Oral Drugs

Dr Antonia F. STEPAN
F. HOFFMANN-LA ROCHE LTD, Basel, Switzerland
15:55

OC02 - Potential of Chloroalkene as Amide Bond Isostere

Prof. Tetsuo NARUMI
SHIZUOKA UNIVERSITY, Hamamatsu, Japan
16:15

OC03 - Scaffold out of the Blue: Azulenes for Medicinal Chemistry

Dr Jörg KLEY
BOEHRINGER INGELHEIM, Biberach an der Riss, Germany
16:35

Coffee Break, Networking & Exhibition

Session 4: Late-Breaking Topics: First Disclosures of Clinical Candidates and Cases Studies

Session chair

Prof. Benoit DEPREZ
INSERM - UNIVERSITÉ DE LILLE / INSTITUT PASTEUR OF LILLE, Lille, France
17:05

PL07 - Discovery of GLPG3970, A First-in-class SIK2/SIK3 Inhibitor Evaluated in Clinical Trials for the Treatment of Autoimmune and Inflammatory Diseases

Dr Christophe PEIXOTO
GALAPAGOS, Romainville, France
17:40

PL08 - Leucettinib-21, A DYRK1A Inhibitor Drug Candidate Aiming at the Correction of Cognitive Disorders in People with Down Syndrome or Alzheimer’s Disease


PERHA PHARMACEUTICALS
18:15

PL09 - Discovery of Linvencorvir (RG7907), a Hepatitis B Virus Core Protein Allosteric Modulator, for the Treatment of Chronic HBV Infection

Dr Wei ZHU
CHINA INNOVATION CENTER OF ROCHE (CICOR), Shanghai, China
18:50

Welcome Reception

20:30

End of the Day

Session 5: Evotec Prize for Excellence in Molecular Design

Session chairs

Dr Jean-Yves ORTHOLAND
EDELRIS, Lyon, France
Dr Christophe BOLDRON
EVOTEC, Toulouse, France
08:45

PL10 - Modulation of Protein – Protein Interactions by Means of Peptidomimetics

Prof. Steven BALLET
VRIJE UNIVERSITEIT BRUSSEL, Brussels, Belgium

Session 6: Neurodegenerative Diseases

Session chair

Prof. Patricia MELNYK
INSERM - UNIVERSITÉ DE LILLE, Lille, France
09:45

PL11 - Structural Biology Supporting Medicinal Chemistry of Purine Receptors

Prof. Christa MÜLLER
UNIVERSITY OF BONN, Bonn, Germany
10:20

OC04 - Unravelling the Potential of the Type 2 Lysophosphatidic Acid Receptor (LPA2) for Central Nervous System Pathologies

Prof. Silvia ORTEGA GUTIERREZ
COMPLUTENSE UNIVERSITY OF MADRID, Madrid, Spain
10:40

Coffee Break, Networking & Exhibition

Session 7: Covalent Inhibitors in Drug Discovery

Session chair

Dr Didier ROCHE
EDELRIS, Lyon, France
11:10

PL12 - Development of SARS Coronavirus 3CL Protease Inhibitors with an Electrophilic aryl-ketone Warhead

Prof. Yoshio HAYASHI
TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES, Tokyo, Japan
11:45

PL13 - Inhibitors of the Mitochrondrial Sirtuins 3 and 5

Prof. Christian A. OLSEN
UNIVERSITY OF COPENHAGEN, Copenhagen, Denmark
12:20

Lunch, Networking & Exhibition

12:35

SCHRÖDINGER WORKSHOP (optional but subject to prior registration)
Augmenting Medicinal Chemistry with Digital Chemistry: a CDK2 Inhibitor Design Challenge

13:15

Poster Session II (posters with even), Networking & Exhibition

Session 8: Next Generation of Anti-infective Agents

Session chair

Dr Baptiste VILLEMAGNE
INSERM - UNIVERSITÉ DE LILLE, Lille, France
14:45

PL14 - BacPROTACs Mediate Targeted Protein Degradation in Bacteria

Prof. Francesca Ester MORREALE
THE FRANCIS CRICK INSTITUTE, London, United Kingdom
15:20

OC05 - Tackling LysS, a New Target for Tuberculosis

Dr Laura A.T. CLEGHORN
UNIVERSITY OF DUNDEE, Dundee, United Kingdom
15:40

OC06 - Historical Evolution and Lessons Learned from an RSV Non Nucleosides Polymerase Inhibitor Program

Dr Sandrine GROSSE
JANSSEN, Beerse, Belgium
16:00

Coffee Break, Networking & Exhibition

16:30

PL15 - Metallo-Enzymes - From Functions to Drugs

Prof. Christopher J. SCHOFIELD
UNIVERSITY OF OXFORD, Oxford, United Kingdom

Session 9: Small Molecules for Immunooncology or Autoimmunity

Session chair

Prof. Rebecca DEPREZ-POULAIN
INSERM - UNIVERSITÉ DE LILLE / INSTITUT PASTEUR OF LILLE, Lille, France
17:05

PL16 - Discovery of the Clinical Candidate ACT-777991, a Potent CXCR3 Antagonist with Therapeutic Potential in Autoimmune Diseases

Dr Eva CAROFF
IDORSIA PHARMACEUTICALS LTD, Allschwil, Switzerland
17:40

OC07 - Discovery of an Oral, Rule-of-5 Compliant, IL-17A Protein-Protein Interaction Modulator (IL-17A PPIm) for the Treatment of Psoriasis and other Inflammatory Diseases.

Dr Mark D. ANDREWS
LEO PHARMA, Ballerup, Denmark
18:00

OC08 - Small-Molecule Inhibitor Targeting PD-1/PD-L1 Interaction Restores T-Cell Function

Prof. Helena FLORINDO
IMED - UNIVERSITY OF LISBON, Lisbon, Portugal
18:20

End of the Day

20:00

Symposium Banquet (subject to prior registration)

Session 10: Beyond PROTACS

Session chair

Dr Guillaume LACONDE
OXELTIS, Montpellier, France
08:45

PL17 - Bifunctional Molecules for Exploring and Treating Human Disease

Prof. David SPIEGEL
YALE UNIVERSITY, New Haven, United States
09:20

PL18 - A Tricycle Journey to in vivo Degraders of the Oncogenic Transcription Factor BCL6

Prof. Swen HOELDER
THE INSTITUTE OF CANCER RESEARCH, Sutton, United Kingdom
09:55

PL19 - Expansion of the Druggable Genome through Rational Approaches to Molecular Glue Discovery

Dr Rohan BECKWITH
NEOMORPH INC., San Diego, United States
10:30

Coffee Break, Networking & Exhibition

Session 11: Galapagos Award For Drug Discovery Chemistry

Session chair

Dr Jean-Yves ORTHOLAND
EDELRIS, Lyon, France
Dr Sandrine VENDEVILLE
GALAPAGOS, Beerse, Belgium
11:00

PL20 - Peptide, A Manifesto

Prof. Philippe KAROYAN
SORBONNE UNIVERSITÉ, VILLEBON SUR YVETTE, France
12:00

Closing Ceremony

12:30

End of the Symposium